# Open-label Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF

> **NCT03785405** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 216 (actual)

## Conditions studied

- Heart Failure

## Interventions

- **DRUG:** sacubitril/valsartan

## Key facts

- **NCT ID:** NCT03785405
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-02
- **Primary completion:** 2023-12-29
- **Final completion:** 2023-12-29
- **Target enrollment:** 216 (ACTUAL)
- **Last updated:** 2025-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03785405

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03785405, "Open-label Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03785405. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*